Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Feb 16, 2022 1:30pm
104 Views
Post# 34434503

RE:RE:RE:RE:RE:RE:RE:Trog IV push data

RE:RE:RE:RE:RE:RE:RE:Trog IV push dataOne needs to be cautious when talking about equivalent doses of TH1902 and docetaxel. By its nature, the PDC, even if it does not enter cells, will allow a higher MTD just because the release of free docetaxel in the bloodstream will be gradual over time, and the Cmax of docetaxel in the blood will be lower. That's why some efficacy signals would be hignly desirable out of phase Ia. Having only safety data will be disapointing and all the question marks will remain. You don't need to have an undeniable proof of concept, but at least good signs pointing towards that.


Wino115 wrote: Outstanding results given the endpoint for 1a is good safety tolerance (compare it to SOC or docetaxol alone at equivalent dose) and the support of a high dose for the extension trial.  That would be outstanding since that's all that is planned.  If the PK/PD can help understand more or if they've actually been able to scan and it's pointing in the right direction, that would be a bonus cake of outstanding. 


<< Previous
Bullboard Posts
Next >>